159 related articles for article (PubMed ID: 18931939)
21. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
[TBL] [Abstract][Full Text] [Related]
22. Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors.
Li X; Hoeppner LH; Jensen ED; Gopalakrishnan R; Westendorf JJ
J Cell Biochem; 2009 Oct; 108(2):378-87. PubMed ID: 19585539
[TBL] [Abstract][Full Text] [Related]
23. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential.
Zaidi SK; Pande S; Pratap J; Gaur T; Grigoriu S; Ali SA; Stein JL; Lian JB; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2007 Dec; 104(50):19861-6. PubMed ID: 18077419
[TBL] [Abstract][Full Text] [Related]
24. Ascorbic acid induces either differentiation or apoptosis in MG-63 osteosarcoma lineage.
Valenti MT; Zanatta M; Donatelli L; Viviano G; Cavallini C; Scupoli MT; Dalle Carbonare L
Anticancer Res; 2014 Apr; 34(4):1617-27. PubMed ID: 24692690
[TBL] [Abstract][Full Text] [Related]
25. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility.
Leong DT; Lim J; Goh X; Pratap J; Pereira BP; Kwok HS; Nathan SS; Dobson JR; Lian JB; Ito Y; Voorhoeve PM; Stein GS; Salto-Tellez M; Cool SM; van Wijnen AJ
Breast Cancer Res; 2010; 12(5):R89. PubMed ID: 21029421
[TBL] [Abstract][Full Text] [Related]
26. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.
Ozaki T; Wu D; Sugimoto H; Nagase H; Nakagawara A
Cell Death Dis; 2013 Apr; 4(4):e610. PubMed ID: 23618908
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Notch Signaling During Osteogenic Differentiation in Human Osteosarcoma Cell Line MG63.
Ongaro A; Pellati A; Bagheri L; Rizzo P; Caliceti C; Massari L; De Mattei M
J Cell Physiol; 2016 Dec; 231(12):2652-63. PubMed ID: 26946465
[TBL] [Abstract][Full Text] [Related]
28. Conditioned medium from bone marrow mesenchymal stem cells transiently retards osteoblast differentiation by downregulating runx2.
Sun J; Zhou H; Deng Y; Zhang Y; Gu P; Ge S; Fan X
Cells Tissues Organs; 2012; 196(6):510-22. PubMed ID: 22906827
[TBL] [Abstract][Full Text] [Related]
29. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression.
Rorke EA; Zhang D; Choo CK; Eckert RL; Jacobberger JW
Exp Cell Res; 2000 Aug; 259(1):149-57. PubMed ID: 10942587
[TBL] [Abstract][Full Text] [Related]
30. The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse.
Quist T; Jin H; Zhu JF; Smith-Fry K; Capecchi MR; Jones KB
Oncogene; 2015 Aug; 34(32):4278-84. PubMed ID: 25347737
[TBL] [Abstract][Full Text] [Related]
31. Ginsenoside Rh1 induces mouse osteoblast growth and differentiation through the bone morphogenetic protein 2/runt-related gene 2 signalling pathway.
Siddiqi MH; Siddiqi MZ; Ahn S; Kim YJ; Yang DC
J Pharm Pharmacol; 2014 Dec; 66(12):1763-73. PubMed ID: 25154440
[TBL] [Abstract][Full Text] [Related]
32. A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells.
Shin MH; He Y; Marrogi E; Piperdi S; Ren L; Khanna C; Gorlick R; Liu C; Huang J
PLoS Genet; 2016 Feb; 12(2):e1005884. PubMed ID: 26925584
[TBL] [Abstract][Full Text] [Related]
33. Coleusin factor, a novel anticancer diterpenoid, inhibits osteosarcoma growth by inducing bone morphogenetic protein-2-dependent differentiation.
Geng S; Sun B; Lu R; Wang J
Mol Cancer Ther; 2014 Jun; 13(6):1431-41. PubMed ID: 24723453
[TBL] [Abstract][Full Text] [Related]
34. RUNX2 controls human IPO8 basal transcription in Saos-2 cells.
Xiong J; Hu Z; Wang T; Xu X; Liu J; Wu P; Che X; Li W
Mol Med Rep; 2016 Aug; 14(2):1418-24. PubMed ID: 27277970
[TBL] [Abstract][Full Text] [Related]
35. RUNX2 and Osteosarcoma.
Li N; Luo D; Hu X; Luo W; Lei G; Wang Q; Zhu T; Gu J; Lu Y; Zheng Q
Anticancer Agents Med Chem; 2015; 15(7):881-7. PubMed ID: 25738872
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells.
Li WW; Fan J; Hochhauser D; Bertino JR
Cancer Res; 1997 Jun; 57(11):2193-9. PubMed ID: 9187120
[TBL] [Abstract][Full Text] [Related]
37. A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation.
Sosa-García B; Gunduz V; Vázquez-Rivera V; Cress WD; Wright G; Bian H; Hinds PW; Santiago-Cardona PG
PLoS One; 2010 Nov; 5(11):e13954. PubMed ID: 21085651
[TBL] [Abstract][Full Text] [Related]
38. Role and regulation of RUNX2 in osteogenesis.
Bruderer M; Richards RG; Alini M; Stoddart MJ
Eur Cell Mater; 2014 Oct; 28():269-86. PubMed ID: 25340806
[TBL] [Abstract][Full Text] [Related]
39. Post-proliferative cyclin E-associated kinase activity in differentiated osteoblasts: inhibition by proliferating osteoblasts and osteosarcoma cells.
Smith E; Frenkel B; MacLachlan TK; Giordano A; Stein JL; Lian JB; Stein GS
J Cell Biochem; 1997 Aug; 66(2):141-52. PubMed ID: 9213216
[TBL] [Abstract][Full Text] [Related]
40. YY1 represses the transcriptional activity of Runx2 in C2C12 cells.
Jeong HM; Choi YH; Lee SH; Lee KY
Mol Cell Endocrinol; 2014 Mar; 383(1-2):103-10. PubMed ID: 24325869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
